| Summary: | Background: The Coronavirus Disease 2019 (COVID-19) vaccine is essential to reduce the spread of this disease virus and is very effective at preventing patients with severe symptoms of the disease from dying. As of February 2022, more than 10 billion doses of the COVID-19 vaccine have been administered worldwide, and at least 60% of the world's population have received the first dose of the vaccine. The increasing number of populations receiving the COVID-19
vaccine has increased reports of post-immunization follow-up events, one of which is urticaria. This study aimed to determine the prevalence and onset of urticaria due to the administration of the COVID-19 vaccine. Methods: This study used a rapid review method based on previous research on the prevalence and onset of urticaria due to the COVID-19
vaccine. The articles were obtained from the PubMed and Google Scholar databases. The inclusion criteria were articles containing data on the prevalence and onset of urticaria due to the COVID-19 vaccine, published from December 2020 – January 2022. Results: From the search results and article selection, 20 articles were included in this study. There are 7 articles containing prevalence data,
11 articles containing onset data, and 2 articles containing prevalence and onset data. Research in these articles was conducted in several different countries. There were seven types of vaccine used with doses of 1 or 2. The sample age ranged from 16 to 76 years. In all of the articles, the sample and the incidence of urticaria were mostly female.
There were a history of allergies and atopic history in the sample studied. Conclusion: The prevalence rate of urticaria in the population given the COVID-19 vaccine ranged from 0.035% to 3.2%. The time of onset of urticaria in the population given the COVID-19 vaccine ranged from 5 minutes to 10 days.
|
|---|